{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:34:48Z","timestamp":1792002888961,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.10.005","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T17:51:19Z","timestamp":1608573079000},"page":"84-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Management of calcium pyrophosphate crystal deposition disease: A systematic review"],"prefix":"10.1016","volume":"51","author":[{"given":"Konstantinos","family":"Parperis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Papachristodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukas","family":"Kakoullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann K.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.10.005_bib0001","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1056\/NEJMra1511117","article-title":"Calcium pyrophosphate deposition disease","volume":"374","author":"Rosenthal","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0002","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00003086-198804000-00023","article-title":"Clinical features of pseudogout attack. A survey of 50 cases","author":"Masuda","year":"1988","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0003","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2010.139105","article-title":"European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0004","first-page":"1515","article-title":"Calcium pyro-phosphate crystal deposition disease; pseudogout; articular chondrocalcinosis","author":"Ryan","year":"1985","journal-title":"Arthritis Allied Cond. Textb. Rheumatol."},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/ard.2010.139105","article-title":"European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: Terminology and diagnosis","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0006","first-page":"e3840","article-title":"Updated treatment for calcium pyrophosphate deposition disease: an insight","volume":"11","author":"Iqbal","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0007","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2010.139360","article-title":"EULAR recommendations for calcium pyrophosphate deposition. Part II: management","volume":"70","author":"Zhang","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0010","unstructured":"Wells G., Shea B., O'Connell D. et\u00a0al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. n.d."},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0011","first-page":"123","article-title":"Primary cutaneous CD4+ small\/medium pleomorphic T-cell lymphoproliferative disorder: Where do we stand? A systematic review","volume":"17","author":"Salah","year":"2019","journal-title":"JDDG - J Ger Soc Dermatology"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0012","first-page":"60","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"Evid Based Med"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0013","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/art.1780230320","article-title":"Intravenous colchicine in the treatment of acute pseudogout","volume":"23","author":"Tabatabai","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0014","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/art.1780230917","article-title":"Colchicine and pseudogout","volume":"23","author":"Spilberg","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0015","unstructured":"FDA. Federal Register: Drug Products Containing Colchicine for Injection; Enforcement Action Dates n.d."},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0016","first-page":"804","article-title":"Colchicine prophylaxis in pseudogout","volume":"13","author":"Alvarellos","year":"1986","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0017","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/art.1780251226","article-title":"Colchicine and pseudogout","volume":"25","author":"Gonz\u00e1lez","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0018","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.22389","article-title":"Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis","volume":"56","author":"Chollet-Janin","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s13075-014-0458-4","article-title":"Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial","volume":"16","author":"Finckh","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0020","first-page":"234","article-title":"Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis","volume":"18","author":"Andres","year":"2012","journal-title":"J Clin Rheumatol Pract Reports Rheum Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0021","first-page":"327","article-title":"Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD","volume":"23","author":"Rothschild","year":"1997","journal-title":"Compr Ther"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0022","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard.42.Suppl_1.106","article-title":"Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy","volume":"42","author":"Doherty","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0023","first-page":"1168","article-title":"Prospective use of intramuscular triamcinolone acetonide in pseudogout","volume":"24","author":"Roane","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1973.03230010020004","article-title":"Pseudogout syndrome in hospital patients","volume":"226","author":"O'duffy","year":"1973","journal-title":"JAMA J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jbspin.2013.05.006","article-title":"ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients","volume":"81","author":"Daoussis","year":"2014","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0026","unstructured":"Synacthen Ampoules 250 micrograms - Summary of Product Characteristics (SmPC) - (emc) n.d."},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0027","first-page":"696","article-title":"ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0028","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jbspin.2012.01.010","article-title":"Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis","volume":"79","author":"Molt\u00f3","year":"2012","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0029","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3899\/jrheum.180393","article-title":"Utility of Anakinra in acute crystalline diseases: a retrospective study comparing a university hospital with a veterans affairs medical center","volume":"46","author":"Desmarais","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jbspin.2012.07.018","article-title":"Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature","volume":"80","author":"Ottaviani","year":"2013","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0031","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10067-018-4272-2","article-title":"Efficacy and tolerance of anakinra in acute calcium pyrophosphate crystal arthritis: a retrospective study of 33 cases","volume":"38","author":"Thomas","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217188","article-title":"Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study","author":"Latourte","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0033","first-page":"3","article-title":"Effects of glycosaminoglycan polysulphate in the treatment of chondrocalcinosis","volume":"6","author":"Sarkozi","year":"1988","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0034","article-title":"Pseudogout and intraarticular hyaluronate injections: comment on the article by Disla Et Al","volume":"43","author":"L","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0035","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0140-6736(81)91488-4","article-title":"Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee","volume":"2","author":"Doherty","year":"1981","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0036","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1089\/pho.2006.24.140","article-title":"Photobiomodulation of pain and inflammation in microcrystalline arthropathies: experimental and clinical results","volume":"24","author":"Soriano","year":"2006","journal-title":"Photomed Laser Surg"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0037","unstructured":"Wells G., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et\u00a0al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses n.d."},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0038","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11926-018-0739-z","article-title":"Therapy for CPPD: options and evidence","volume":"20","author":"Andr\u00e9s","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0039","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.semarthrit.2014.02.003","article-title":"Treatment of acute gout: a systematic review","volume":"44","author":"Khanna","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0040","first-page":"1001","article-title":"Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review","volume":"38","author":"Cipolletta","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0041","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pop.2018.02.004","article-title":"Diagnosis and treatment of gout and pseudogout for everyday practice","volume":"45","author":"Sidari","year":"2018","journal-title":"Prim Care"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0042","article-title":"Colchicine for acute gout","volume":"2014","author":"van Echteld","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0043","first-page":"32","article-title":"Update on calcium pyrophosphate deposition","volume":"34","author":"Abhishek","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.10.005_bib0044","unstructured":"Pseudogout and intraarticular hyaluronate injections: Comment on the article by Disla et\u00a0al n.d. https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/1529-0131%28200007%2943%3A7%3C1657%3A%3AAID-ANR37%3E3.0.CO%3B2-4 (Accessed June 24, 2020)."}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:46Z","timestamp":1758733426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220302985"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.005","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of calcium pyrophosphate crystal deposition disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}